Recently reported that the COVID-19 vaccine produced by AstraZeneca was due to increased reports of blood clots for vaccine recipients.
This resulted in a delay in the use of the AstraZeneca vaccine in 12 countries in Europe, including Europe and France. This news made Thailand the first country apart from Europe to delay the launch of its vaccine program.
However, the World Health Organization (WHO) and the European Medicines Agency (EMA) have confirmed that cases of blood clots in Europe are not related to the use of the AstraZeneca vaccine. AstraZeneca also stated that it had conducted a review of data from 17 million people vaccinated in the European Union and the UK and failed to find any increased risk of blood clots due to the vaccine, which they developed.
How about in Indonesia? Indonesia is one of the Asia Pacific countries which has a supply of 1,113,600 doses of AstraZeneca's COVID-19 vaccine currently owned by the government. This time, the use of AstraZeneca is still waiting for studies from the Food and Drug Administration (BPOM) and the National Immunization Expert (ITAGI). The government is still reviewing the safety of vaccines related to the news of these side effects. Plus, the AstraZeneca vaccine interval period is longer than Sinovac. The AstraZeneca vaccine takes 9 to 12 weeks, with the current AstraZeneca vaccine expiring in May 2021.
Currently, market players are concerned that the progress of the vaccine program could hamper so that the process towards economic recovery will take longer.
A week ago, the index managed to gain + 1.6% as a result of the signing of the US government's US $ 1.9 trillion fiscal stimulus package. However, earlier this week, the index looked quite depressed due to several external and internal factors, such as the AstraZeneca vaccine issue. The volatility of the domestic stock market this week will provide opportunities for investors to average asset classes such as stocks. The total number of vaccines ordered by the Indonesian government from several vaccine manufacturers reached 538 million doses until Q1-2022, with the largest provider of vaccines from Sinovac. There are also several additional producers such as Sinopharm, Moderna, Red and White vaccines which are currently in the development stage and clinical trials in Indonesia.
The decline in the number of spread and the rate of domestic mortality will be the main support for the stock market going forward as the government strives to obtain a sufficient supply of the COVID-19 vaccine for Indonesia to achieve "herd immunity"